Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Liabilities and Shareholders Equity (2022 - 2025)

Historic Liabilities and Shareholders Equity for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Q3 2025 value amounting to $513.8 million.

  • Day One Biopharmaceuticals' Liabilities and Shareholders Equity fell 1448.5% to $513.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 billion, marking a year-over-year increase of 2617.61%. This contributed to the annual value of $582.8 million for FY2024, which is 5497.7% up from last year.
  • As of Q3 2025, Day One Biopharmaceuticals' Liabilities and Shareholders Equity stood at $513.8 million, which was down 1448.5% from $519.0 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' 5-year Liabilities and Shareholders Equity high stood at $600.8 million for Q3 2024, and its period low was $267.8 million during Q1 2022.
  • Over the past 4 years, Day One Biopharmaceuticals' median Liabilities and Shareholders Equity value was $404.0 million (recorded in 2022), while the average stood at $429.7 million.
  • Examining YoY changes over the last 5 years, Day One Biopharmaceuticals' Liabilities and Shareholders Equity showed a top increase of 6358.92% in 2025 and a maximum decrease of 1448.5% in 2025.
  • Quarter analysis of 4 years shows Day One Biopharmaceuticals' Liabilities and Shareholders Equity stood at $349.1 million in 2022, then rose by 7.73% to $376.0 million in 2023, then soared by 54.98% to $582.8 million in 2024, then dropped by 11.84% to $513.8 million in 2025.
  • Its last three reported values are $513.8 million in Q3 2025, $519.0 million for Q2 2025, and $534.4 million during Q1 2025.